Naramig (Naratriptan)

Naratriptan is a selective 5‑HT1B/1D receptor agonist. By stimulating these serotonin receptors on cranial blood vessels and trigeminal nerve fibers, it causes vasoconstriction and blocks the release of pain‑inducing neuropeptides, thereby aborting a migraine attack.

The specific dose of Naramig is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for naratriptan in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing Naramig to pregnant or nursing women, and discuss alternative options when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naramig (naratriptan) belongs to the triptan class, which is generally more migraine‑specific than non‑specific analgesics such as NSAIDs. Compared with other triptans, naratriptan has a longer half‑life, offering a prolonged effect, but individual response and tolerability can vary.

Naramig tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Naramig is taken orally, usually as a whole tablet with a glass of water. It should be taken as soon as migraine symptoms begin, and patients should not exceed the maximum daily dose recommended by their prescriber.

Serious risks include chest pain or tightness, cardiac arrhythmias, severe hypertension, serotonin syndrome when combined with other serotonergic agents, and rare ischemic events such as stroke or myocardial infarction. Patients should seek immediate medical attention if any of these symptoms occur.

Naramig is contraindicated in patients with known hypersensitivity to naratriptan or any triptan, uncontrolled hypertension, significant cardiovascular disease, history of stroke or transient ischemic attack, and in those currently taking MAO inhibitors or other triptans.